Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06985147 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
A Phase 2 study of Polycythemia Vera (PV), sponsored by Disc Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 14
- Study locations
NCT06985147: Recruiting Phase 2 study of Polycythemia Vera (PV), sponsored by Disc Medicine.
NCT06985147 is a Phase 2 study of Polycythemia Vera (PV) that is actively recruiting participants, run by Disc Medicine. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06985147, a Phase 2 study of Polycythemia Vera (PV), is actively recruiting participants, sponsored by Disc Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 14
- Study locations
Study Summary
This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).
Primary Outcome
Proportion of participants with treatment-emergent adverse events
Conditions Studied
Interventions
- DRUG DISC-3405
Study Locations (14)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- UCLA Health - Los Angeles
- Keck Medicine of USC - Cancer Clinic- Newport Beach - Newport Beach
North Carolina
- Atrium Health - Levine Cancer Center - Charlotte
- Duke University - Durham
- Atrium Health Wake Forest Baptist Medical Center - Winston-Salem
Arizona
- Mayo Clinic in Arizona - Phoenix
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Minnesota - Rochester
Missouri
- Siteman Cancer Center - Washington University St. Louis - St Louis
Ohio
- Ohio State University - Columbus
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
What NCT06985147 shows while recruiting
NCT06985147 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Polycythemia Vera (PV) appearing as the primary indexed condition, and to 1 intervention - of which DISC-3405 is the first listed.
NCT06985147 lists 14 locations in 10 states (California, North Carolina, Arizona).
Frequently Asked Questions
What is clinical trial NCT06985147 about?
NCT06985147 is a clinical study titled "A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)". This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).
What is the current status of trial NCT06985147?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-08-12. Estimated completion is 2029-02.
What conditions does trial NCT06985147 study?
This clinical trial studies the following conditions: Polycythemia Vera (PV).
What interventions are being tested in trial NCT06985147?
The interventions under investigation include: DISC-3405 (DRUG).
Who is sponsoring clinical trial NCT06985147?
This trial is sponsored by Disc Medicine, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06985147 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycythemia Vera (PV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06985147's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI